$4.96
-0.30 (-5.70%)
Open$5.34
Previous Close$5.26
Day High$5.34
Day Low$4.90
52W High$7.75
52W Low$3.71
Volume—
Avg Volume212.1K
Market Cap123.38M
P/E Ratio—
EPS$-1.27
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+642.9% upside
Current
$4.96
$4.96
Target
$36.85
$36.85
$27.29
$36.85 avg
$45.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.26M | 21.48M | 20.04M |
| Net Income | -38,087,173 | -5,165,355 | -3,853,498 |
| Profit Margin | -267.1% | -24.1% | -19.2% |
| EBITDA | -38,033,136 | -6,655,427 | -5,995,002 |
| Free Cash Flow | — | -3,535,951 | -2,421,928 |
| Rev Growth | — | -8.7% | +0.8% |
| Debt/Equity | — | 0.24 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |